Protocol Ledger

NCT04440059 · Phase II · COMPLETED

A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

Interventional Phase II clinical trial protocol NCT04440059 sponsored by Beijing InnoCare Pharma Tech Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-08-10 Enrollment: 47 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04440059
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)47 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04440059
Protocol FieldVerified Registry Value
NCT IdentifierNCT04440059
Consolidated Lead SponsorBeijing InnoCare Pharma Tech Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment47 participants (ACTUAL)
Registered Start Date2019-08-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04440059
Hospital Research SiteLocationSite Profile
The First Affiliated Hospital of Xiamen UniversityXiamen, ChinaOpen Hospital Dossier ->
Henan Cancer HospitalZhengzhou, ChinaOpen Hospital Dossier ->
Jiangsu Province HospitalNanjing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI